“Any vaccination you get, there are side effects,” Witkamp said. “But the benefits of getting the vaccination definitely outweigh them. There are people dying from the swine flu.

“Some of my friends call us guinea pigs, but they are not fully informed. The vaccination that they will be studying will be the same that anyone can get at the health department [when it is approved].”

Witkamp and her girls, Baylee, 3, and Emmie, 5, are among thousands of people rolling up their sleeves for science as drug companies, doctors and government officials work to get a safe and effective swine flu vaccine on the market by October.

In June, the World Health Organization declared a global pandemic of H1N1, or the swine flu, which has killed more than 300 and sickened more than 43,000 in the U.S. In Texas, 5,373 cases have been reported, with 357 confirmed in Dallas County and 210 in Tarrant County, according to the Texas Department of State Health Services.

Officials expect to see those numbers rise when school starts, which is why large-scale clinical trials are being conducted worldwide.

In Fort Worth, Benchmark Research is conducting clinical trials for several drug companies, testing to see patients’ reactions to the experimental vaccine and whether it produces an immune response to the H1N1 virus. Benchmark, which is paying patients $200 to $600, depending on the study and its protocol, will begin administering injections next week.

“What we are doing is private and independent,” said Dr. William Seger, Benchmark’s principal investigator, who also has a private medical practice next door. “These are private companies that are developing the flu vaccine, and they need to prove to the FDA that they are acceptable. They may be the one to help bring us a vaccine that is first to the market. We are going to need them all to produce the gazillion H1N1s that we are going to need worldwide.”

Although studies are being conducted on all ages, Seger especially needs patients 6 months to 17 years old, the population that is most likely to come into contact with H1N1.

Australia’s government ordered 10 million doses of swine flu vaccine being developed by pharmaceutical company CSL Ltd (CSL.AX) on Thursday as the number of confirmed H1N1 cases in Australia topped 100.

Health Minister Nicola Roxon said the government would also buy a further 1.6 million courses of antiviral drug Relenza to bolster the national stockpile to 10.3 million courses of anti-viral drugs.

“We are working very hard to contain this,” Roxon told reporters in Canberra, where she confirmed the number of swine flu story”>H1N1 cases had climbed from 61 on Wednesday to 103 by Thursday.

Most cases were in Australia’s most populous states of New South Wales and Victoria in the country’s south east, which are heading into the southern winter and regular flu season.

Of the confirmed cases, three are on a cruise liner, the Pacific Dawn, which will now return to a major port rather than continue with its planned voyage north to the state of Queensland.

Roxon said CSL expects its swine flu story”>H1N1 vaccine to be ready within a few months, with the company planning to start clinical trials to make sure the vaccine is safe and effective for human use.

The supply would cover just less than half of Australia’s 21 million people, but Roxon said medical authorities would priorities which areas and people would most need the vaccine.

The government has also approved the first release of anti-viral drugs from the national stockpile, with 7,500 doses of paediatric Tamiflu to be relased in the Victoria and Western Australia states, and 10,000 packets of Tamiflu to Victoria.

“These localised releases from the stockpile will enable aggressive containment of small clusters of the disease,” Roxon said.